Explore the words cloud of the ETVAX project. It provides you a very rough idea of what is the project "ETVAX" about.
The following table provides information about the project.
SCANDINAVIAN BIOPHARMA HOLDING AB
|Coordinator Country||Sweden [SE]|
|Total cost||2˙992˙750 €|
|EC max contribution||2˙992˙750 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-06-01 to 2020-05-31|
Take a look of project's partnership.
|1||SCANDINAVIAN BIOPHARMA HOLDING AB||SE (SOLNA)||coordinator||2˙992˙750.00|
This project will perform a Phase II study of ETVAX – an oral vaccine against traveller’s diarrhoea (TD) caused by enterotoxigenic E. coli bacteria (ETEC). ETVAX has a strong potential to be the first vaccine with a full ETEC indication. TD caused by enterotoxigenic E. coli bacteria is the most common illness that affects travellers traveling in the developing regions. Currently, there is no approved method for preventing TD.
Travellers are recommended to use off-label antibiotics such as Rifaximin or the cholera vaccine Dukoral to prevent TD. In business terms, there exists a strong business opportunity in developing and commercializing an effective and safe ETEC vaccine. Scandinavian Biopharma is the first SME positioned to capture this opportunity. The envisaged Phase II study will allow Scandinavian Biopharma take the key step towards the commercialization of ETVAX.
The targeted users of are travellers visiting tropical and subtropical countries. Their number is forecasted to reach 190 million by 2020. Their key need is to prevent TD which can ruin a significant part of a vacation or a business trip. ETVAX will meet this needs by being safe, efficient and easy to use.
The project delivers an ultimate EU added value by offering the first ETEC vaccine with proven immunogenicity, safety and efficacy. From the scientific perspective, this means that the project fills the gap in the vaccine research on the EU and global level as no other efficient methods for prevention of TD have been proposed on the market to date. The introduction of ETVAX will ultimately decrease number of TD cases among travellers, decrease number of patients with irritable bowel syndrome or other chronic diseases connected to TD, as well as decrease healthcare costs and productivity losses on the EU level.
If successfully validated and accepted by regulatory bodies, ETVAX will take Scandinavian Biopharma to a new level of competitiveness and growth.
|Approval letter from Ethics Committee||Documents, reports||2020-01-28 16:23:38|
|Approval letter from the Finnish Medicine Agency Fimea||Documents, reports||2020-01-28 16:23:38|
Take a look to the deliverables list in detail: detailed list of ETVAX deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ETVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ETVAX" are provided by the European Opendata Portal: CORDIS opendata.
Translational studies of HEAD and neck cancer in South America and EuropeRead More
A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients.Read More
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone MetastasisRead More